Book contents
- Stahl’s Self-Assessment Examination in Psychiatry
- Stahl’s Self-Assessment Examination in Psychiatry
- Copyright page
- Contents
- Introduction/Preface
- CME/CE Information
- 1 ADHD and Its Treatment
- 2 Anxiety/Stress Disorders and Their Treatment
- 3 Basic Neuroscience and Pharmacological Concepts
- 4 Bipolar Disorder and Its Treatment
- 5 Chronic Neuropathic Pain and Its Treatment
- 6 Dementia and Its Treatment
- 7 Psychosis and Its Treatment
- 8 Sleep/Wake Disorders and Their Treatment
- 9 Substance Use/Impulsive-Compulsive Disorders and Their Treatment
- 10 Unipolar Depression and Its Treatment
- Index
- References
6 - Dementia and Its Treatment
Published online by Cambridge University Press: 22 July 2022
Book contents
- Stahl’s Self-Assessment Examination in Psychiatry
- Stahl’s Self-Assessment Examination in Psychiatry
- Copyright page
- Contents
- Introduction/Preface
- CME/CE Information
- 1 ADHD and Its Treatment
- 2 Anxiety/Stress Disorders and Their Treatment
- 3 Basic Neuroscience and Pharmacological Concepts
- 4 Bipolar Disorder and Its Treatment
- 5 Chronic Neuropathic Pain and Its Treatment
- 6 Dementia and Its Treatment
- 7 Psychosis and Its Treatment
- 8 Sleep/Wake Disorders and Their Treatment
- 9 Substance Use/Impulsive-Compulsive Disorders and Their Treatment
- 10 Unipolar Depression and Its Treatment
- Index
- References
Summary
Harold, a 74-year-old patient, is brought to your office by his daughter, who reports that her father has been exhibiting several concerning symptoms over the past year. Comprehensive questioning reveals that his symptoms are: trouble remembering familiar things, such as telephone numbers commonly dialed; not recognizing some close family members who visit often; and difficulty performing writing tasks. The patient’s motor function appears to be unaffected. Although not definitive, these symptoms are most likely indicative of which type of dementia?
- Type
- Chapter
- Information
- Stahl's Self-Assessment Examination in PsychiatryMultiple Choice Questions for Clinicians, pp. 179 - 206Publisher: Cambridge University PressPrint publication year: 2022
References
References
Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 12)CrossRefGoogle Scholar
Stahl, SM, Morrissette, DA. Stahl’s illustrated Alzheimer’s disease and other dementias. New York, NY: Cambridge University Press; 2018.Google Scholar
References
Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 12)CrossRefGoogle Scholar
Woolf, NJ, Butcher, LL. Cholinergic systems mediate action from movement to higher consciousness. Behav Brain Res 2011;221(2):488–98.CrossRefGoogle ScholarPubMed
References
Barnes, DE, Yaffe, K, Byers, AL et al. Midlife versus late-life depressive symptoms and risk of dementia: differential effects for Alzheimer’s disease and vascular dementia. Arch Gen Psychiatry 2012;69(5):493–8.Google Scholar
Pomara, N, Bruno, D, Sarreal, AS et al. Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am J Psychiatry 2012;169:523–30.CrossRefGoogle ScholarPubMed
Stahl, SM, Morrissette, DA. Stahl’s illustrated Alzheimer’s disease and other dementias. New York, NY: Cambridge University Press; 2018.Google Scholar
References
Atwood, CS, Bishop, GM, Perry, G et al. Amyloid beta: a vascular sealant that protects against hemorrhage? J Neurosci Res 2002;70(3):356.CrossRefGoogle ScholarPubMed
Kokjohn, TA, Maarfouf, CL, Roher, AE. Is Alzheimer’s disease amyloidosis the result of a repair mechanism gone astray? Alzheimers Dement 2012;8(6):574–83.Google Scholar
Kumar, DK, Choi, SH, Washicosky, KJ et al. Amyloid-beta peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease. Sci Transl Med 2016;8(340):340ra72.CrossRefGoogle ScholarPubMed
Stahl, SM, Morrissette, DA. Stahl’s illustrated Alzheimer’s disease and other dementias. New York, NY: Cambridge University Press; 2018.Google Scholar
References
Stahl, SM. Stahl’s essential psychopharmacology, the prescriber’s guide, seventh edition. New York, NY: Cambridge University Press; 2020.Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 12)Google Scholar
References
Kotermanski, SE, Johnson, JW. Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer’s drug memantine. J Neurosci 2009;29(9):2774–9.Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 12)CrossRefGoogle Scholar
Stahl, SM, Morrissette, DA. Stahl’s illustrated Alzheimer’s disease and other dementias. New York, NY: Cambridge University Press; 2018.CrossRefGoogle Scholar
References
Alzheimer’s Association. 2016 Alzheimer’s disease facts and figures. Alzheimers Dement 2016;12(4):459–509.CrossRefGoogle Scholar
Godyń, J, Jończyk, J, Panek, D et al. Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol Rep 2016;68:127–38.CrossRefGoogle ScholarPubMed
Harrison, JR, Owen, MJ. Alzheimer’s disease: the amyloid hypothesis on trial. Br J Psychiatry 2016;208(1):1–3.CrossRefGoogle ScholarPubMed
Panza, F, Seripa, D, Solfrizzi, V et al. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients. Expert Opin Emerg Drugs 2016;21(4):377–91.CrossRefGoogle ScholarPubMed
Pedersen, JT, Sigurdsson, EM. Tau immunotherapy for Alzheimer’s disease. Trends Mol Med 2015;21(6):394–402.CrossRefGoogle ScholarPubMed
References
Giri, M, Zhang, M, Lu, Y. Genes associated with Alzheimer’s disease: an overview and current status. Clin Interv Aging 2016;11:665–81.Google Scholar
Hinz, FI, Geschwind, DH. Molecular genetics of neurodegenerative dementias. Cold Spring Harb Perspect Biol 2017;9(4):a023705.Google Scholar
Rosenberg, RN, Lambracht-Washington, D, Yu, G et al. Genomics of Alzheimer disease: a review. JAMA Neurol 2016;73(7):867–74.CrossRefGoogle ScholarPubMed
Schellenberg, GD, Montine, TJ. The genetics and neuropathology of Alzheimer’s disease. Acta Neuropathol 2012;124(3):305–23.CrossRefGoogle ScholarPubMed
Reference
Stahl, SM, Morrissette, DA. Stahl’s illustrated Alzheimer’s disease and other dementias. New York, NY: Cambridge University Press; 2018.Google Scholar
Reference
McKhann, GM, Knopman, DS, Chertkow, H et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7(3):263–9.CrossRefGoogle ScholarPubMed
References
Ford, AH. Preventing delirium in dementia: managing risk factors. Maturitas 2016;92:35–40.Google Scholar
Lippmann, S, Perugula, ML. Delirium or dementia? Innov Clin Neurosci 2016;13(9–10):56–7.Google Scholar
Reference
Stahl, SM, Morrissette, DA. Stahl’s illustrated Alzheimer’s disease and other dementias. New York, NY: Cambridge University Press; 2018.CrossRefGoogle Scholar
Reference
Hodgson, NA, Gitlin, LN, Winter, L et al. Undiagnosed illness and neuropsychiatric behaviors in community residing older adults with dementia. Alzheimer Dis Assoc Disord 2011;25:109–15.Google Scholar
References
Canevelli, M, Valleta, M, Trebbastoni, A et al. Sundowning in dementia: clinical relevance, pathophysiological determinants, and therapeutic approaches. Front Med (Lausanne) 2016;3:73.Google Scholar
Satlin, A, Volicer, L, Ross, V et al. Bright light treatment of behavioral and sleep disturbances in patients with Alzheimer’s disease. Am J Psychiatry 1992;149(8):1028–32.Google ScholarPubMed
Skjerve, A, Nygaard, HA. Improvement in sundowning in dementia with Lewy bodies after treatment with donepezil. Int J Geriatr Psychiatry 2000;15(12):1147–51.Google Scholar
Stahl, SM, Morrissette, DA. Stahl’s illustrated Alzheimer’s disease and other dementias. New York, NY: Cambridge University Press; 2018.Google Scholar